培美曲塞联合免疫抑制剂激素如何使用?

2021-07-28 MedSci原创 MedSci原创

培美曲塞联合免疫抑制剂激素如何使用-2021肺癌免疫治疗进展-问题5.

《梅斯直播课:肺癌诊疗训练营——2021肺癌免疫治疗进展》

回答问题5:培美曲塞联合免疫抑制剂激素如何使用?

 

欢迎点赞、评论、分享

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1807502, encodeId=6f15180e502e4, content=<a href='/topic/show?id=f248e99592d' target=_blank style='color:#2F92EE;'>#美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79959, encryptionId=f248e99592d, topicName=美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 08 00:45:05 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852718, encodeId=9eeb1852e1873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Dec 19 07:45:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286303, encodeId=b2c6128630392, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395296, encodeId=3aeb1395296fb, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41632, encryptionId=0e7041632f3, topicName=培美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003322, encodeId=3cd8100332277, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/3bcc8a19b5134fdf896f4523428930a7/66e5fa7eeebb4ee9a931a2be23a32a3d.jpg, createdBy=9e745542029, createdName=卢兵, createdTime=Wed Jul 28 14:12:03 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1807502, encodeId=6f15180e502e4, content=<a href='/topic/show?id=f248e99592d' target=_blank style='color:#2F92EE;'>#美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79959, encryptionId=f248e99592d, topicName=美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 08 00:45:05 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852718, encodeId=9eeb1852e1873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Dec 19 07:45:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286303, encodeId=b2c6128630392, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395296, encodeId=3aeb1395296fb, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41632, encryptionId=0e7041632f3, topicName=培美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003322, encodeId=3cd8100332277, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/3bcc8a19b5134fdf896f4523428930a7/66e5fa7eeebb4ee9a931a2be23a32a3d.jpg, createdBy=9e745542029, createdName=卢兵, createdTime=Wed Jul 28 14:12:03 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-12-19 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1807502, encodeId=6f15180e502e4, content=<a href='/topic/show?id=f248e99592d' target=_blank style='color:#2F92EE;'>#美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79959, encryptionId=f248e99592d, topicName=美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 08 00:45:05 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852718, encodeId=9eeb1852e1873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Dec 19 07:45:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286303, encodeId=b2c6128630392, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395296, encodeId=3aeb1395296fb, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41632, encryptionId=0e7041632f3, topicName=培美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003322, encodeId=3cd8100332277, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/3bcc8a19b5134fdf896f4523428930a7/66e5fa7eeebb4ee9a931a2be23a32a3d.jpg, createdBy=9e745542029, createdName=卢兵, createdTime=Wed Jul 28 14:12:03 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1807502, encodeId=6f15180e502e4, content=<a href='/topic/show?id=f248e99592d' target=_blank style='color:#2F92EE;'>#美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79959, encryptionId=f248e99592d, topicName=美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 08 00:45:05 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852718, encodeId=9eeb1852e1873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Dec 19 07:45:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286303, encodeId=b2c6128630392, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395296, encodeId=3aeb1395296fb, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41632, encryptionId=0e7041632f3, topicName=培美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003322, encodeId=3cd8100332277, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/3bcc8a19b5134fdf896f4523428930a7/66e5fa7eeebb4ee9a931a2be23a32a3d.jpg, createdBy=9e745542029, createdName=卢兵, createdTime=Wed Jul 28 14:12:03 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1807502, encodeId=6f15180e502e4, content=<a href='/topic/show?id=f248e99592d' target=_blank style='color:#2F92EE;'>#美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79959, encryptionId=f248e99592d, topicName=美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 08 00:45:05 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852718, encodeId=9eeb1852e1873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Dec 19 07:45:05 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286303, encodeId=b2c6128630392, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395296, encodeId=3aeb1395296fb, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41632, encryptionId=0e7041632f3, topicName=培美曲塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Jul 30 04:45:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003322, encodeId=3cd8100332277, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/3bcc8a19b5134fdf896f4523428930a7/66e5fa7eeebb4ee9a931a2be23a32a3d.jpg, createdBy=9e745542029, createdName=卢兵, createdTime=Wed Jul 28 14:12:03 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-07-28 卢兵

    很好

    0

相关资讯

Science Translational Medicine:A20下调促进肺癌免疫逃逸,是肺癌发展的新检查点

近日,维也纳医科大学的研究团队在 Science 子刊 Science Translational Medicine 发表了题为:Down-regulation of A20 promotes imm

今晚直播:60分钟解读肺癌免疫治疗新近进展

👉 30篇肺癌最新指南报名即得,前200位可申领肿瘤专业纸质书1本

Radiology:在判断肺癌浸润性时,每个影像科医生都该认识的征象!

肺癌占全球所有癌症相关死亡的四分之一,其中肺癌最常见的组织学亚型为肺腺癌。根据多学科分类对肺腺癌的侵袭性进行评价,该分类包括原位癌(AIS)、微浸润性腺癌(MIA)和浸润性腺癌(IVA)。

ASCO2021:遵循数据,消除偏见,肺癌防治在行动

遵循数据,消除偏见,肺癌防治在行动

BMJ子刊:较高强度的运动或抵消睡眠不足带来的健康危害

轻度运动-睡眠不佳组合的参与者具有较高的全因、总心血管疾病、冠心病和肺癌的死亡风险。

拓展阅读

肺癌脑转、脑膜转后,化疗药培美曲塞能助靶向药奥希替尼一臂之力!

对于存在脑部转移病灶的肺癌,最理想的情况是使用入脑能力较强的靶向药,尽管观察到奥希替尼有较好的入脑能力,但是仍然有部分患者不能受益。

Thorac Cancer:EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS

EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS,但是也增加了不良反应。

培美曲塞:提前1周 or 同期应用叶酸及VB12?超全用药说明来了

培美曲塞是一种多靶点的叶酸拮抗剂。

ESMO Open:奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性

奥希替尼联合化疗在 EGFRm 的晚期/转移性 NSCLC 中具有可控的安全性和耐受性

J Thorac Oncol:EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性

该研究表明50mg培美曲塞鞘内注射治疗TKI治疗进展的EGFR 突变NSCLC脑膜转移患者毒性较低,并且有较好的临床缓解。